Akero (AKRO) Form 4: Young Sells ~12.5k Shares, Gains 12.5k Options
Rhea-AI Filing Summary
Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 plan. He acquired 12,500 stock options at an exercise price of $21.10 and exercised options that resulted in ownership of 82,482 common shares in total. On the same date he sold 12,500 common shares via a market sale at a weighted-average price of $21.10 (option acquisition) and separately sold 8,299 shares at a weighted-average price of $47.644 and 4,201 shares at a weighted-average price of $47.984. Following the reported transactions, he directly beneficially owned 196,898 shares. He also holds indirect interests of 20,000 shares each through three irrevocable trusts for his children, which he disclaims as beneficial ownership.
Positive
- Acquired 12,500 stock options at an exercise price of $21.10
- Direct beneficial ownership of 196,898 shares following transactions
- Indirect holdings of 60,000 shares held in irrevocable trusts for children
Negative
- Sold 8,299 shares at a weighted-average price of $47.644
- Sold 4,201 shares at a weighted-average price of $47.984
Insights
Insider sold 12,500 shares and sold additional 12,500 via 10b5-1 on 10/01/2025.
The Report shows a mix of option activity and open-market sales executed under a Rule 10b5-1 trading plan dated 04/29/2025. The filing records acquisition of 12,500 options at an exercise price of $21.10 and multiple sales totaling 24,?00 shares across two weighted-average sale-price ranges: $46.94–$47.93 and $47.94–$48.22, summarized as weighted-average prices of $47.644 and $47.984.
Because transactions were effected under a pre-established plan, they are mechanically executed rather than necessarily reflecting new company-specific information; the filing discloses direct beneficial ownership of 196,898 shares after the trades and indirect holdings of 60,000 shares in three irrevocable trusts for his children.
Transactions include option vesting schedule and trust-held shares.
The option reported vests in 48 equal monthly installments beginning 12/08/2021, and the Form discloses the standard disclaimer that trust-held shares are not claimed as beneficially owned. The signature on the Form is dated 10/03/2025, confirming timely reporting.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | -- |
| Exercise | Common Stock | 12,500 | $21.10 | $264K |
| Sale | Common Stock | 8,299 | $47.644 | $395K |
| Sale | Common Stock | 4,201 | $47.984 | $202K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025, previously adopted by the Reporting Person. These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.93, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.94 to $48.22, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2021
